Atomo Diagnostics pushes ahead with IPO, boosted by COVID-19 prospects
Atomo, backed by billionaire developer Lang Walker, is working with several manufacturing customers to develop a rapid blood self-test for COVID-19.
Despite market turmoil, Atomo Diagnostics – the biotech backed by billionaire developer Lang Walker and former Macquarie bank boss Allan Moss – is pushing head with its planned ASX float after receiving increased interest on the back of the conronavirus pandemic.
Late last week its broker, Canaccord Genuity, mulled pulling the initial public offer but in light of the heightened interest from four diagnostic companies in China, Europe and the United States about its self-testing blood kits for coronavirus, Atomo is still seeking to raise $30 million at 20¢ a share.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Healthcare & fitness
Fetching latest articles